Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chemotactic factor CCL8 in preparation of dermatomyositis condition and prognosis evaluation reagent

A prognostic assessment and chemokine technology, which can be used in disease diagnosis, biological testing, material testing, etc.

Active Publication Date: 2019-12-10
NANJING DRUM TOWER HOSPITAL
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Researchers have reported that chemokines CXCL10, CX3CL1, CXCL8, and CCL2 are associated with disease activity in patients with dermatomyositis. chemokine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chemotactic factor CCL8 in preparation of dermatomyositis condition and prognosis evaluation reagent
  • Application of chemotactic factor CCL8 in preparation of dermatomyositis condition and prognosis evaluation reagent
  • Application of chemotactic factor CCL8 in preparation of dermatomyositis condition and prognosis evaluation reagent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] 1. Sample selection and processing

[0024] Experimental group (DM): Take fresh peripheral blood from patients with dermatomyositis (DM) and centrifuge to separate the plasma, then quickly put it into a cryopreservation tube and store it in a -80°C refrigerator for later use;

[0025] Control group (HC): Fresh peripheral blood was collected from age- and gender-matched healthy people (HC) without immune diseases, and the plasma was separated by centrifugation, then quickly put into cryopreservation tubes, and stored in a -80°C refrigerator for later use.

[0026] 2. Screening and verification of plasma chemokines in patients with diabetes mellitus

[0027] 2.1) Screening: In this experiment, we used the AAH-CYT-G5 protein chip purchased from RayBiotech to analyze the plasma samples of 16 healthy people and 16 patients with DM, and systematically compared and analyzed the plasma samples of HC and DM patients. Expression differences of various chemokines; by figure 1 Th...

Embodiment 2

[0051] A test kit for dermatomyositis condition and prognosis assessment, said test kit comprising:

[0052] a) container;

[0053] b) a specific antibody for the CCL8 protein contained in the container;

[0054] c) a label or an instruction for use, which indicates that the kit is used for evaluating the condition of dermatomyositis and using the kit to predict the prognosis of DM patients in the label or the instruction for use.

[0055] Further, the label or instructions for use indicate: when the plasma CCL8 value of a DM patient is ≥67.3pg / ml, the patient is diagnosed as having a severe condition and poor prognosis; when the plasma CCL8 value of a patient with dermatomyositis is <67.3pg / ml, The patient was diagnosed with a mild condition and a good prognosis.

[0056] Utilize above-mentioned detection kit of the present invention, quantitatively detect 129 routine DM patient's plasma samples (with DM characteristic erythra (Xiangyang rash or Gottron sign) appearing for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological diagnosis and medicine, and particularly relates to an application of a chemotactic factor CCL8 in preparation of a dermatomyositis condition and prognosis evaluation reagent. According to the invention, a patient plasma specimen for definite diagnosis of dermatomyositis is used as a research object; protein chip detection is carried out; a sample is expanded; a protein chip result is verified by an ELISA method; by combining biochemical indexes and clinical manifestation judgment correlation of patients, it is proved that the blood plasma CCL8level of dermatomyositis patients is remarkably higher than that of healthy people, the expression level of the blood plasma CCL8 is related to the illness state and prognosis of the patients, the blood plasma CCL8 level of dermatomyositis patients effective in treatment is remarkably reduced, and CCL8 can aggravate pulmonary lesions of interstitial pneumonia mice. Therefore, the CCL8 can be usedas a potential biomarker to be applied to a reagent for evaluating the illness state and prognosis of dermatomyositis patients, experimental data and theoretical basis are provided for the applicationof the CCL8 to the illness state and prognosis evaluation of the dermatomyositis patients, and the invention further provides a corresponding kit for evaluating the illness state and prognosis of thedermatomyositis patients.

Description

technical field [0001] The invention relates to the fields of biological diagnosis and medicine, in particular to the application of chemokine CCL8 in the preparation of dermatomyositis condition and prognosis evaluation reagents. Background technique [0002] Dermatomyositis (DM) is a type of autoimmune inflammatory myopathy with characteristic skin lesions, non-suppurative inflammatory changes of skeletal muscle and progressive muscle weakness as the main clinical manifestations. The pathogenesis is still unclear. Patients with dermatomyositis are often complicated with interstitial lung disease (ILD), and some patients have rapid progression of lung lesions and poor prognosis. At present, clinical evaluation is mainly based on the patient's clinical manifestations and some laboratory test indicators (such as kinases, C-reactive protein, serum ferritin, and myositis-specific antibody titers, etc.) to comprehensively evaluate the condition. There have been many studies try...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/531
CPCG01N33/531G01N33/6893G01N2800/202
Inventor 孙凌云张昕陈智勇余迪
Owner NANJING DRUM TOWER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com